<； p >； The present Invention relates to pharmaceutical formulations of 509 - RNA that can be administered to a Mammalian, particularly Human,Who has a disease or AFECCI u00d3N receptor related ANDROG u00c9NICO (RA), more particularly cancer, particularly prostate cancer, including, but not limited toCastration resistant prostate cancer, with Prostate Cancer metastasis resistant to Castration.Prostate Cancer With metastasis resistant to Castration without prior Treatment with Chemotherapy.Prostate Cancer Hormone Sensitive Prostate Cancer Biochemistry with recurrence or not metast u00c1sico Castration resistant and high risk.In One aspect, these formulations comprise a Solid dispersion of RNA - 509 and a Copolymer of Poly (meth) acrylic acid.In One aspect, The Solid dispersion of RNA - 509 and a Copolymer of Poly (meth) acrylic acid can be obtained, particularly is obtainedThrough the extrusion by Fusion of a mixture comprising RNA - 509 and a Copolymer of Poly (meth) acrylic acid and, Optionally, grinding the mixture subsequently Extruded by merger.In One aspect, The Solid dispersion of ARL - 509 and a Copolymer of Poly (meth) acrylic acid can be obtained, particularly is obtainedThrough dehydration by spray a mixture comprising RNA - 509 and a Copolymer of Poly (meth) acrylic acid in a suitable solvent. <； / p >；La presente solicitud describe a una dispersión sólida que comprende ARN-509 o apalutamida y HPMCAS, una partícula que consiste en la dispersión sólida, una composición farmacéutica que comprende la dispersión sólida que comprende ARN-509 y HPMCAS, y un vehiculo farmacéuticamente aceptable, un procedimiento de preparación de la dispersión sólida que comprende ARN-509 y HPMCAS, y el uso de la dispersión sólida que comprende ARN-509 y HPMCAS para tratar un cáncer de próstata.
